Emerging phagocytosis checkpoints in cancer immunotherapy

Новые контрольные точки фагоцитоза в иммунотерапии рака
Qi Wu, Yue Liu, Yanjin Wang, Yanrong Yang, Linjun Weng, Jin Zhang, Pengcheng Zhao, Lan Fang, Yufeng Shi, Ping Wang
2023-03-07

CD47adoptive cell therapycancer immunotherapydon't eat me signalsphagocytosis checkpoints
Cancer immunotherapy, mainly including immune checkpoints-targeted therapy and the adoptive transfer of engineered immune cells, has revolutionized the oncology landscape as it utilizes patients' own immune systems in combating the cancer cells. Cancer cells escape immune surveillance by hijacking the corresponding inhibitory pathways via overexpressing checkpoint genes. Phagocytosis checkpoints, such as CD47, CD24, MHC-I, PD-L1, STC-1 and GD2, have emerged as essential checkpoints for cancer immunotherapy by functioning as "don't eat me" signals or interacting with "eat me" signals to suppress immune responses. Phagocytosis checkpoints link innate immunity and adaptive immunity in cancer immunotherapy. Genetic ablation of these phagocytosis checkpoints, as well as blockade of their signaling pathways, robustly augments phagocytosis and reduces tumor size. Among all phagocytosis checkpoints, CD47 is the most thoroughly studied and has emerged as a rising star among targets for cancer treatment. CD47-targeting antibodies and inhibitors have been investigated in various preclinical and clinical trials. However, anemia and thrombocytopenia appear to be formidable challenges since CD47 is ubiquitously expressed on erythrocytes. Here, we review the reported phagocytosis checkpoints by discussing their mechanisms and functions in cancer immunotherapy, highlight clinical progress in targeting these checkpoints and discuss challenges and potential solutions to smooth the way for combination immunotherapeutic strategies that involve both innate and adaptive immune responses.
1
Because CD47 is ubiquitously expressed on erythrocytes, CD47-targeted therapies face major risks of anemia and thrombocytopenia, motivating combination strategies and potential solutions.
2
CD47 is the most extensively studied phagocytosis checkpoint, with antibodies and inhibitors evaluated in preclinical and clinical trials.
3
Genetic ablation or pathway blockade of phagocytosis checkpoints robustly enhances phagocytosis and reduces tumor size.
4
Phagocytosis checkpoints, including CD47, CD24, MHC-I, PD-L1, STC-1, and GD2, suppress antitumor immunity through “don’t eat me” signals or interactions with “eat me” signals.
5
These checkpoints connect innate and adaptive immunity, making them important targets for cancer immunotherapy.

Phagocytosis checkpoints in cancer (e.g., CD47, CD24, MHC-I, PD-L1, STC-1, GD2)

Their roles and mechanisms as “don’t eat me” signals that suppress phagocytosis and antitumor immunity, and the therapeutic effects, clinical progress, and challenges of blocking these pathways

Publication Details
Publication Date
2023-03-07
Journal
Publisher
ISSN
Cited by
286
Access Type
Author Information
Authors
Qi Wu
Yue Liu
Yanjin Wang
Yanrong Yang
Linjun Weng
Jin Zhang
Pengcheng Zhao
Lan Fang
Yufeng Shi
Ping Wang
Explore further
Open the scid.ai AI chat with a ready-made request: it will find papers on a similar topic and help build a literature review.
Find similar papers in the chat →
Make a presentation
100%